Xconomy
JULY 2, 2018
A paper published last week in the journal JAMA Oncology makes the case that one such test, Oncotype DX AR-V7 Nucleus Detect, might be worth its $3,980 price tag. Blood tests for cancer, known as liquid biopsies, have become available in recent years to guide treatments for people already diagnosed. But how useful are they?
Xconomy
SEPTEMBER 6, 2019
In presenting clinical data from a Phase 3 study. If MedCo’s cholesterol-lowering drug inclisiran wins FDA approval, it will become the third entry in a new class of medicines that block a cholesterol-boosting protein called PCSK9. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
OCTOBER 28, 2016
THIS WEEK IN DRUG PRICING…. —A coalition of investors pressed drug makers to justify price increases. The group filed shareholder resolutions with 11 companies and cited a Kaiser Family Foundation poll that cited Americans’ concerns over drug prices. AND DUCHENNE.
Xconomy
MARCH 17, 2017
The data, from a massive study of more than 27,000 patients, come at a time when drug and healthcare prices are a top U.S. political issue, and pricey new cholesterol drugs have been a key battleground.
Xconomy
OCTOBER 7, 2016
—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. PRICE FIGHTS. With some caveats, ICER recommended lower prices. She refused to discuss Edison at the time. —The U.S.
TechCrunch LA
MAY 25, 2019
For one, because millennials, according to various studies, are consuming less alcohol than previous generations and are therefore seeking non-alcoholic beverage alternatives. From wellness chat and journaling apps to therapy substitutes to fitness companies, stick wellness in a pitch and investors will take a second look.
Xconomy
SEPTEMBER 7, 2016
Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. The company plans to present detailed results at an upcoming medical meeting or in a peer-reviewed journal, it said in a statement.
Expert insights. Personalized for you.
81 
Let's personalize your content